On April 24, 2017, the Department of Community Health and Network Coordination under the Viet Nam National Institute of Hygiene (NIHE) and Epidemiology organized a kick-off meeting on microarray patch acceptability and usability evaluation in low and middle income countries. This project is in the collaboration between NIHE and Agence De Medicine Preventive (AMP) and the World Health Organization. Representatives from Ministry of Health, National EPI office, NIHE, AMP, WHO, UNICEF, PATH, GaneshAID and the BacKan province where pilots the project attended the meeting.
The project is conducted in three countries including Viet Nam, Nepal and Benin to test the acceptability and usability of the microarray patch which is expected to replace the projection measle vaccine.
Delivered a speech in the meeting, the Director of NIHE shared that currently more than 20 millions infants have note been vaccinated measles on time, over 134,000 measles deaths globally in 2014. Specifically in Viet Nam of which the goal to eradicate measles in 2012. However, Vietnam faced with more than 7,000 cases of mealses in children from 1-5 years and 18-26 years old. A big campaign of measle vaccine projection was conducted in 2016.
MAP for measles is an array of small solid-coated, or dissolvable needles with 10,000 microprojections on 01 cm2 surface, containing a dry formulation of a vaccine. The microarry patch is placed on skin with a medical stick. This patch is expected to help erase the limitations of traditional vaccination including cold chain, packaging footprint, administration and waste.
The micro array patch has been presented to the WHO Strategic Advisory Group of Expert MR working Group and to SAGE. These two organizations encouraged to further study on this innovation.
The assessment of acceptability and usability is being conducted in Vietnam from April to December. The results ill be evidence to provide specific recommendations to WHO and the MAP developers on elements in the current product which could be improved to increase the acceptability and usability of MAP vaccination.